Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R
Sponsor: OHSU Knight Cancer Institute
A PHASE2 clinical study on Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative and Chronic Neutrophilic Leukemia, this trial is completed. The trial is conducted by OHSU Knight Cancer Institute and has accumulated 11 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Mar 2020 — Dec 2020 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jul 2018 — Mar 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- OHSU Knight Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .